Circulating activated protein C levels are not increased in septic patients treated with recombinant human soluble thrombomodulin

BACKGROUND: Recombinant human soluble thrombomodulin (rTM) has been used for the treatment of disseminated intravascular coagulation in Japan, and an international phase III clinical trial for rTM is currently in progress. rTM mainly exerts its anticoagulant effects through an activated protein C (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Arishima, Takuro, Ito, Takashi, Yasuda, Tomotsugu, Yashima, Nozomi, Furubeppu, Hiroaki, Kamikokuryo, Chinatsu, Futatsuki, Takahiro, Madokoro, Yutaro, Miyamoto, Shotaro, Eguchi, Tomohiro, Haraura, Hiroyuki, Maruyama, Ikuro, Kakihana, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161343/
https://www.ncbi.nlm.nih.gov/pubmed/30275773
http://dx.doi.org/10.1186/s12959-018-0178-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161343/
https://www.ncbi.nlm.nih.gov/pubmed/30275773
http://dx.doi.org/10.1186/s12959-018-0178-0

Ejemplares similares